Intravenous neridronate in adults with osteogenesis imperfecta

Journal of Bone and Mineral Research

Volumn 18, Issue 1, 2003, Pages 126-130

  Adami, S ^a,b   Gatti, D ^a   Colapietro, F ^a   Fracassi, E ^a   Braga, V ^a   Rossini, M ^a   Tato L ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Ospedale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; NERIDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MALE; OSTEOGENESIS IMPERFECTA; PREMENOPAUSE; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; PEPTIDES;

EID: 0037215352     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.1.126     Document Type: Article

References (29)

1. Smith R 1986 Osteogenesis imperfecta. Clin Rheum Dis 12:655-689.
2. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116.
3. Castells S 1973 New approaches to treatment of osteogenesis imperfecta. Clin Orthop 93:239-249.
4. Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, Rosenfeld R, Chrousos GP 1993 The growth hormone and somatomedian axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 76:251-256.
5. Horewitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK 2001 Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97:1227-1231.
6. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C 1987 Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363.
7. Huaux JP, Lokietek W 1988 Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8:71-72.
8. Brumsen C, Hamdy NAT, Papapoulos SE 1997 Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283.
9. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G 1997 Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622-625.
10. Åström E, Söderhäll S 1998 Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Pediatr 87:64-68.
11. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J 2001 Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529-533.
12. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
13. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
14. Fleisch H 2000 Bisphosphonates: Mechanism of action. Endocrinol Rev 19:80-100.
15. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA 1987 Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8(Suppl 1):S35-S41.
16. Delmas PD, Chapuy MC, Edouard C, Meunier PJ 1987 Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 83:276-282.
17. Atkins RM, Yates AJ, Gray RE, Urwin GH, Hamdy NA, Beneton MN, Rosini S, Kanis JA 1987 Aminohexane diphosphonate in the treatment of Paget, s disease of bone. J Bone Miner Res 2:273-9.
18. Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V 2002 Short-term intravenous therapy with neridronate in Paget's disease. Clin Exper Rheumatol 220:55-58.
19. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR for the Study of Osteoporotic Fractures Research Group 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984-996.
20. WHO 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical report series, 843, World Health Organization, Geneva, Switzerland.
21. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, LoCascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
22. Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates: A comparative review. Drug Safety 14:158-170.
23. Baron R, Gertner JM, Lang R, Vignery A 1983 Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 17:204-207.
24. Brenner RE, Vetter U, Bollen Am, Mörike M, Eyre DR 1994 Bone resorption assessed by immunoassay of urinary cross linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 9:993-997.
25. Glorieux FH, Travers R, Chabot G, Lanoue G 1994 Bone histomorphometric analysis in osteogenesis imperfecta. J Bone Miner Res 9(Suppl 1):S226.
26. Hockberg MA, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
27. Adami S, Kanis JA 1995 Assessment of involutional bone loss: Methodological and conceptual problems. J Bone Miner Res 10: 511-517.
28. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer SR, Stock JL, Yood RA, Delmas PD, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
29. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282: 1344-1352.